JP2010530245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530245A5 JP2010530245A5 JP2010513254A JP2010513254A JP2010530245A5 JP 2010530245 A5 JP2010530245 A5 JP 2010530245A5 JP 2010513254 A JP2010513254 A JP 2010513254A JP 2010513254 A JP2010513254 A JP 2010513254A JP 2010530245 A5 JP2010530245 A5 JP 2010530245A5
- Authority
- JP
- Japan
- Prior art keywords
- alphavirus
- rna molecule
- rna
- protein
- recognition sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000710929 Alphavirus Species 0.000 claims description 90
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 80
- 101710172711 Structural protein Proteins 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 26
- 230000010076 replication Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 108090000565 Capsid Proteins Proteins 0.000 claims description 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 6
- 101710125507 Integrase/recombinase Proteins 0.000 claims description 6
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims description 6
- 108091081024 Start codon Proteins 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 3
- 101800000120 Host translation inhibitor nsp1 Proteins 0.000 claims description 2
- 108020005350 Initiator Codon Proteins 0.000 claims description 2
- 101710128560 Initiator protein NS1 Proteins 0.000 claims description 2
- 101710144127 Non-structural protein 1 Proteins 0.000 claims description 2
- 101800000512 Non-structural protein 1 Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663707P | 2007-06-21 | 2007-06-21 | |
| US60/936,637 | 2007-06-21 | ||
| PCT/US2008/007701 WO2008156829A2 (en) | 2007-06-21 | 2008-06-20 | Promoterless cassettes for expression of alphavirus structural proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014167257A Division JP5995926B2 (ja) | 2007-06-21 | 2014-08-20 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530245A JP2010530245A (ja) | 2010-09-09 |
| JP2010530245A5 true JP2010530245A5 (cg-RX-API-DMAC7.html) | 2012-06-21 |
| JP5602624B2 JP5602624B2 (ja) | 2014-10-08 |
Family
ID=40156867
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513254A Active JP5602624B2 (ja) | 2007-06-21 | 2008-06-20 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| JP2014167257A Active JP5995926B2 (ja) | 2007-06-21 | 2014-08-20 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| JP2016162382A Withdrawn JP2016198114A (ja) | 2007-06-21 | 2016-08-23 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014167257A Active JP5995926B2 (ja) | 2007-06-21 | 2014-08-20 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| JP2016162382A Withdrawn JP2016198114A (ja) | 2007-06-21 | 2016-08-23 | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8460913B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2947149B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5602624B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101802199B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008266807B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2689588C (cg-RX-API-DMAC7.html) |
| DK (2) | DK2183368T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2588906T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL202720A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ582495A (cg-RX-API-DMAC7.html) |
| PL (2) | PL2183368T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008156829A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200909080B (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2183368T3 (en) * | 2007-06-21 | 2016-09-05 | Alphavax Inc | PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS |
| ES2525707T3 (es) | 2008-12-01 | 2014-12-29 | Alphavax, Inc. | Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus |
| WO2010118244A1 (en) | 2009-04-08 | 2010-10-14 | Alphavax, Inc. | Alphavirus Replicon Particles Expressing TRP2 |
| HRP20160805T1 (hr) | 2010-07-06 | 2016-08-12 | Glaxosmithkline Biologicals Sa | Imuniziranje velikih sisavaca malim dozama rna |
| LT3243526T (lt) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Rnr pristatymas, skirtas keleto imuninio atsako paleidimui |
| CA2804396C (en) | 2010-07-06 | 2021-06-29 | Novartis Ag | Liposomes with lipids having an advantageous pka-value for rna delivery |
| SI3981427T1 (sl) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Pegilirani liposomi za dostavo imunogen-kodirajoče RNA |
| CN103269713B (zh) | 2010-10-11 | 2016-01-20 | 诺华有限公司 | 抗原递送平台 |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| EP3105311A1 (en) | 2014-02-10 | 2016-12-21 | Univercells NV | System, apparatus and method for biomolecules production |
| EP4101930A1 (en) | 2015-09-17 | 2022-12-14 | ModernaTX, Inc. | Polynucleotides containing a stabilizing tail region |
| US10022436B2 (en) | 2016-01-11 | 2018-07-17 | Verndari, Inc. | Microneedle compositions and methods of using same |
| WO2017162266A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| US12385034B2 (en) | 2016-06-24 | 2025-08-12 | Modernatx, Inc. | Methods and apparatus for filtration |
| CN110073002B (zh) * | 2016-10-17 | 2024-06-11 | 杨森制药公司 | 重组病毒复制子体系及其用途 |
| CA3045650A1 (en) | 2016-12-05 | 2018-06-14 | Synthetic Genomics, Inc. | Compositions and methods for enhancing gene expression |
| TW201907937A (zh) | 2017-05-08 | 2019-03-01 | 美商葛利史東腫瘤科技公司 | 阿爾法病毒新抗原載體 |
| US20200283497A1 (en) * | 2017-09-13 | 2020-09-10 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing at cell receptor or an artificial t cell receptor |
| CN111094549B (zh) * | 2017-09-13 | 2024-11-01 | 生物技术公司 | 用于将体细胞重编程的rna复制子 |
| JP7731670B2 (ja) | 2017-11-06 | 2025-09-01 | インターベット インターナショナル ベー． フェー． | ネコ白血病ウイルスワクチン |
| US11229699B2 (en) | 2017-11-06 | 2022-01-25 | Intervet Inc. | Feline calicivirus vaccine |
| CA3080430A1 (en) | 2017-11-06 | 2019-06-13 | Intervet International B.V. | Feline calicivirus vaccine |
| CA3080425A1 (en) | 2017-11-06 | 2019-05-09 | Intervet International B.V. | Rabies virus vaccine |
| JP2021505560A (ja) | 2017-12-04 | 2021-02-18 | インターベット インターナショナル ベー． フェー． | イヌライム病ワクチン |
| KR20250116783A (ko) | 2017-12-04 | 2025-08-01 | 인터벳 인터내셔널 비.브이. | 레플리콘 입자 및 오일 아주반트를 사용한 예방접종 |
| AU2018380582B2 (en) | 2017-12-08 | 2025-08-14 | Intervet International B.V. | Feline calicivirus vaccine |
| JP7427585B2 (ja) | 2017-12-15 | 2024-02-05 | インターベット インターナショナル ベー． フェー． | 多価ネコワクチン |
| CN111491663B (zh) | 2017-12-18 | 2024-08-20 | 英特维特国际股份有限公司 | 猪甲型流感病毒疫苗 |
| EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| MX2020006567A (es) | 2017-12-20 | 2020-09-25 | Vlp Therapeutics Llc | Particula de replicon de alfavirus. |
| KR20200111729A (ko) | 2018-01-19 | 2020-09-29 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진 |
| US12331076B2 (en) | 2018-10-08 | 2025-06-17 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
| WO2020127730A1 (en) | 2018-12-20 | 2020-06-25 | Intervet International B.V. | Prime-boost vaccination regimen |
| IL288283B2 (en) | 2019-05-30 | 2025-05-01 | Gritstone Bio Inc | Modified adenovirus |
| EP4117725A4 (en) * | 2020-03-09 | 2024-05-29 | Arcturus Therapeutics, Inc. | CORONAVIRUS VACCINE COMPOSITIONS AND METHODS |
| TWI891771B (zh) | 2020-04-17 | 2025-08-01 | 美商Ｖｌｐ醫療股份有限公司 | 冠狀病毒疫苗 |
| IL297564A (en) | 2020-04-30 | 2022-12-01 | Vlp Therapeutics Inc | Cytokine immunotherapy |
| WO2021228731A1 (en) | 2020-05-11 | 2021-11-18 | Intervet International B.V. | Feline severe acute respiratory syndrome coronavirus 2 vaccine |
| EP4168429A1 (en) | 2020-06-19 | 2023-04-26 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus |
| CN115697398A (zh) | 2020-06-19 | 2023-02-03 | 英特维特国际股份有限公司 | 包含两种不同rna复制子颗粒的甲型猪流感病毒疫苗 |
| CN115768472A (zh) * | 2020-06-19 | 2023-03-07 | 英特维特国际股份有限公司 | 包含具有特定基因顺序的核酸构建体的甲型猪流感病毒疫苗 |
| WO2021255221A1 (en) | 2020-06-19 | 2021-12-23 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages |
| IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
| KR20230065321A (ko) | 2020-09-07 | 2023-05-11 | 인터벳 인터내셔널 비.브이. | Ha 항체-양성 표적을 위한 ha 스템 백신 |
| MX2023005495A (es) | 2020-11-12 | 2023-05-23 | Intervet Int Bv | Vectores recombinantes que codifican para proteinas espiculares quimericas del coronavirus y uso de los mismos. |
| CN118139640A (zh) | 2021-10-25 | 2024-06-04 | 英特维特国际股份有限公司 | 保护仔猪抵抗甲型猪流感病毒感染的疫苗 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) * | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| NZ225583A (en) | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
| US5217879A (en) * | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| US6770283B1 (en) | 1990-12-13 | 2004-08-03 | Bioption Ab | DNA expression systems based on alphaviruses |
| US20020102273A1 (en) | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
| AU6172194A (en) * | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
| RU2057377C1 (ru) | 1993-08-23 | 1996-03-27 | Уральский электрохимический комбинат | Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов |
| DE69433461T2 (de) | 1993-09-15 | 2004-11-18 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Rekombinanter Alphavirus Vektor |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5505947A (en) * | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| FR2723849B1 (fr) * | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US5639650A (en) | 1995-05-23 | 1997-06-17 | The University Of North Carolina At Chapel Hill | cDNA clone for South African Arbovirus No. 86 |
| US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US6197879B1 (en) * | 1995-10-31 | 2001-03-06 | Henkel Corporation | Methods of preparing inorganic pigment dispersions |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6448389B1 (en) * | 1996-04-23 | 2002-09-10 | The Wistar Institute Of Anatomy And Biology | Human cytomegalovirus DNA constructs and uses therefor |
| US5853719A (en) * | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| JP2000514290A (ja) * | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| JP2965908B2 (ja) | 1996-07-05 | 1999-10-18 | 株式会社精工技研 | 調温液体シール手段を備える光ディスク成形用金型装置 |
| US5827658A (en) | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
| US5726022A (en) | 1996-11-18 | 1998-03-10 | Lifespan Biosciences, Inc. | Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences |
| KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
| FR2757169B1 (fr) * | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin |
| US5811407A (en) * | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| US5958738A (en) | 1997-03-24 | 1999-09-28 | Roche Diagnostics Corporation | Procedure for subtractive hybridization and difference analysis |
| US6261570B1 (en) * | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
| GB9716611D0 (en) | 1997-08-07 | 1997-10-08 | Cantab Pharmaceuticals Res Ltd | Virus preparations and methods |
| AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| US6197502B1 (en) | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
| GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| FI106618B (fi) | 1998-03-30 | 2001-03-15 | Sandvik Tamrock Oy | Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä |
| JP2002510647A (ja) | 1998-04-08 | 2002-04-09 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 癌の治療のための方法および修飾細胞 |
| US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
| EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
| US7267823B2 (en) * | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
| CA2336554A1 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
| EP1119626B1 (en) * | 1998-07-10 | 2008-01-02 | U.S. Army Medical Research Institute of Infectious Diseases | Botulinum neurotoxin vaccine |
| ATE443768T1 (de) | 1998-07-10 | 2009-10-15 | U S Medical Res Inst Of Infect | Impfstoff gegen staphylokokken-vergiftung |
| US6770479B1 (en) | 1998-07-10 | 2004-08-03 | The United States Of America As Represented By The Secretary Of The Army | Anthrax vaccine |
| JP2002526421A (ja) | 1998-10-05 | 2002-08-20 | ジェンザイム・コーポレーション | 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子 |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| ATE465266T1 (de) | 1998-12-31 | 2010-05-15 | Novartis Vaccines & Diagnostic | Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren |
| US6329201B1 (en) * | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| CA2360347C (en) | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| DE60044125D1 (de) | 1999-04-14 | 2010-05-20 | Novartis Vaccines & Diagnostic | Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme |
| DE60040672D1 (de) | 1999-08-31 | 2008-12-11 | Univ North Carolina | Antikörper-abhängige vergrösserung der alphavirus-infektvität |
| CA2385823A1 (en) * | 1999-10-01 | 2001-04-12 | Haifeng Chen | Production of recombinant aav using adenovirus comprising aav rep/cap genes |
| US7115391B1 (en) * | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| DK1285080T3 (da) | 2000-05-31 | 2008-12-01 | Novartis Vaccines & Diagnostic | Fremgangsmåde til oprensning af alphavirusreplikonpartikler |
| WO2002003917A2 (en) | 2000-07-07 | 2002-01-17 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified hiv genes for use as vaccines |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| AU2002227506A1 (en) | 2000-07-28 | 2002-02-13 | Visteon Global Technologies, Inc. | An air intake arrangement for an internal combustion engine |
| CA2424052A1 (en) * | 2000-08-29 | 2002-03-07 | Wyeth Holdings Corporation | Packaging of positive-strand rna virus replicon particles |
| AU2001290642A1 (en) | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
| DE10049587A1 (de) * | 2000-10-06 | 2002-05-02 | Icon Genetics Ag | Vektorsystem für Pflanzen |
| DE10061150A1 (de) | 2000-12-08 | 2002-06-13 | Icon Genetics Ag | Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen |
| US6800289B2 (en) * | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
| JP2005502591A (ja) * | 2001-01-12 | 2005-01-27 | カイロン コーポレイション | 核酸粘膜免疫 |
| DE10121283B4 (de) | 2001-04-30 | 2011-08-11 | Icon Genetics GmbH, 80333 | Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen |
| DE60236864D1 (de) * | 2001-05-31 | 2010-08-12 | Novartis Vaccines & Diagnostic | Chimere alphavirus-replikon-partikel |
| US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| DE10143237A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente) |
| DE10143238A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente |
| JP4790984B2 (ja) * | 2001-09-06 | 2011-10-12 | アルファヴァックス，インコーポレイテッド | アルファウイルスレプリコンベクター系 |
| AU2003222068A1 (en) | 2002-03-25 | 2003-10-13 | University Of North Carolina At Chapel Hill | Improved methods for achieving expression from alphavirus vectors |
| JP3857195B2 (ja) | 2002-07-09 | 2006-12-13 | 株式会社東芝 | 距離継電装置 |
| WO2004043399A2 (en) * | 2002-11-13 | 2004-05-27 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| DK2290054T3 (en) * | 2002-12-13 | 2017-07-03 | Alphavax Inc | Alpha virus particles and processes for their preparation |
| US20040208848A1 (en) * | 2002-12-13 | 2004-10-21 | Smith Jonathan F. | Multi-antigenic alphavirus replicon particles and methods |
| NZ542353A (en) | 2003-03-20 | 2008-07-31 | Alphavax Inc | Improved alphavirus replicons and helper constructs |
| US20060099587A1 (en) * | 2003-06-20 | 2006-05-11 | Johnston Robert E | Alphavirus vectors having attentuated virion structural proteins |
| ES2327643T3 (es) * | 2003-07-11 | 2009-11-02 | Alphavax, Inc. | Vacunas contra citomegalovirus basadas en alfavirus. |
| EP1687033A4 (en) * | 2003-11-12 | 2008-06-11 | Us Navy | IMPROVEMENT OF VACCINE-INDUCED IMMUNE REACTIONS AND PROTECTION THROUGH HETEROLOGY REINFORCEMENT WITH ALPHAVIRUS REPLICON VACCINE |
| US7078087B2 (en) * | 2003-12-31 | 2006-07-18 | Kimberly-Clark Worldwide, Inc. | Wipes with an edge treatment along a leading edge portion |
| US20050266550A1 (en) | 2004-05-18 | 2005-12-01 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
| AU2005327198B2 (en) * | 2004-07-09 | 2011-03-31 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| EP1856250B1 (en) * | 2005-02-15 | 2013-07-24 | The University of North Carolina At Chapel Hill | New live virus vaccines |
| AU2007296489B2 (en) * | 2006-09-12 | 2013-07-04 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| DK2183368T3 (en) | 2007-06-21 | 2016-09-05 | Alphavax Inc | PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS |
| JP5758632B2 (ja) * | 2008-01-24 | 2015-08-05 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ | 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用 |
-
2008
- 2008-06-20 DK DK08825920.5T patent/DK2183368T3/en active
- 2008-06-20 EP EP15173487.8A patent/EP2947149B1/en active Active
- 2008-06-20 AU AU2008266807A patent/AU2008266807B2/en active Active
- 2008-06-20 DK DK15173487.8T patent/DK2947149T3/en active
- 2008-06-20 US US12/665,497 patent/US8460913B2/en active Active
- 2008-06-20 NZ NZ582495A patent/NZ582495A/en unknown
- 2008-06-20 US US12/143,320 patent/US7850977B2/en active Active
- 2008-06-20 ES ES08825920.5T patent/ES2588906T3/es active Active
- 2008-06-20 WO PCT/US2008/007701 patent/WO2008156829A2/en not_active Ceased
- 2008-06-20 CA CA2689588A patent/CA2689588C/en active Active
- 2008-06-20 PL PL08825920.5T patent/PL2183368T3/pl unknown
- 2008-06-20 ES ES15173487.8T patent/ES2670813T3/es active Active
- 2008-06-20 CN CN2008801036605A patent/CN101802199B/zh active Active
- 2008-06-20 EP EP08825920.5A patent/EP2183368B1/en active Active
- 2008-06-20 PL PL15173487T patent/PL2947149T3/pl unknown
- 2008-06-20 JP JP2010513254A patent/JP5602624B2/ja active Active
-
2009
- 2009-12-14 IL IL202720A patent/IL202720A/en active IP Right Grant
- 2009-12-18 ZA ZA200909080A patent/ZA200909080B/xx unknown
-
2014
- 2014-08-20 JP JP2014167257A patent/JP5995926B2/ja active Active
-
2016
- 2016-08-23 JP JP2016162382A patent/JP2016198114A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530245A5 (cg-RX-API-DMAC7.html) | ||
| Rauch et al. | New vaccine technologies to combat outbreak situations | |
| Rayner et al. | Alphavirus vectors and vaccination | |
| Anraku et al. | Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity | |
| Schlesinger | Alphaviruses—vectors for the expression of heterologous genes | |
| Emonet et al. | Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies | |
| Gorchakov et al. | Selection of functional 5′ cis-acting elements promoting efficient Sindbis virus genome replication | |
| Le Nouën et al. | Attenuation of human respiratory viruses by synonymous genome recoding | |
| JP2020510426A5 (cg-RX-API-DMAC7.html) | ||
| JP2015527296A5 (cg-RX-API-DMAC7.html) | ||
| JP2015522581A5 (cg-RX-API-DMAC7.html) | ||
| Atasheva et al. | Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation | |
| CN103088049A (zh) | 日本脑炎病毒sa14-14-2株基于dna的感染性克隆、其构建方法及应用 | |
| WO2023035372A1 (zh) | 一种有限自我复制mRNA分子系统、制备方法及应用 | |
| EP3158059B1 (en) | Method for rapid generation of an attenuated rna virus | |
| JP2025169275A5 (cg-RX-API-DMAC7.html) | ||
| Conradie et al. | Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus | |
| Ren et al. | Recent advances in Bunyavirus reverse genetics research: systems development, applications, and future perspectives | |
| Pereira-Gómez et al. | Altering compositional properties of viral genomes to design live-attenuated vaccines | |
| EP3158060B1 (en) | Method for rapid generation of an infectious rna virus | |
| Hewson | RNA viruses: emerging vectors for vaccination and gene therapy | |
| CN118086288A (zh) | 多顺反子的自放大rna及制备方法 | |
| Lundstrom | Self-replicating RNA viral vectors in vaccine development and gene therapy | |
| JP2011507515A5 (cg-RX-API-DMAC7.html) | ||
| CN115725657A (zh) | 一种节段化的水泡性口炎病毒载体及其制备方法和应用 |